| Literature DB >> 35456257 |
Yohann Dabi1,2, Samia Ouasti2, Hélène Didelot3, Henri Wohrer3, Dounia Skalli3, Gregoire Miailhe3, Jennifer Uzan3, Clément Ferrier2, Sofiane Bendifallah1,2, Bassam Haddad3,4, Emile Daraï1,2, Cyril Touboul1,2.
Abstract
Our objective was to evaluate postoperative pain and opioid consumption in patients undergoing hysterectomy by low-impact laparoscopy and compare these parameters with conventional laparoscopy. We conducted a prospective study in two French gynecological surgery departments from May 2017 to January 2018. The primary endpoint was the intensity of postoperative pain evaluated by a validated numeric rating scale (NRS) and opioid consumption in the postoperative recovery unit on Day 0 and Day 1. Thirty-two patients underwent low-impact laparoscopy and 77 had conventional laparoscopy. Most of the patients (90.6%) who underwent low-impact laparoscopy were managed as outpatients. There was a significantly higher consumption of strong opioids in the conventional compared to the low-impact group on both Day 0 and Day 1: 26.0% and 36.4% vs. 3.1% and 12.5%, respectively (p = 0.02 and p < 0.01). Over two-thirds of the patients in the low-impact group did not require opioids postoperatively. Two factors were predictive of lower postoperative opioid consumption: low-impact laparoscopy (OR 1.38, 95%CI 1.13-1.69, p = 0.002) and a mean intraoperative peritoneum below 10 mmHg (OR 1.25, 95%CI 1.03-1.51). Total hysterectomy by low-impact laparoscopy is feasible in an outpatient setting and is associated with a marked decrease in opioid consumption compared to conventional laparoscopy.Entities:
Keywords: hysterectomy; low impact laparoscopy; opioids; postoperative pain
Year: 2022 PMID: 35456257 PMCID: PMC9030666 DOI: 10.3390/jcm11082165
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Main patient characteristics.
| Conventional Laparoscopy | Low-Impact Laparoscopy | ||
|---|---|---|---|
| Age, median (sd) | 48.3 (13.0) | 52.9 (12.5) | 0.74 |
| BMI ≥30 | 15 (19.5) | 4 (12.5) | 0.58 |
| Menopausal | 32 (41.6) | 17 (53.1) | 0.30 |
| ASA physical status * | 0.06 | ||
| Class 1 | 29 (37.7) | 20 (62.5) | |
| Class 2 | 42 (54.5) | 11 (34.4) | |
| Class 3 | 6 (7.8) | 1 (3.1) | |
| Comorbidity ** | 24 (31.2) | 8 (25) | 0.65 |
| Increased bleeding risk | 7 (9.1) | 0 | |
| Systemic disease | 3 (3.9) | 3 (9.4) | |
| Diabetes | 5 (6.5) | 0 | |
| Hypertension | 13 (16.9) | 3 (9.4) | |
| Other | 1 (1.3) | 2 (6.3) | |
| Cesarean section | 0.18 | ||
| Category 1 | 14 (18.2) | 2 (6.3) | |
| Category 2 | 9 (11.7) | 6 (18.8) | |
| Category 3 | 1 (1.3) | 0 | |
| History of abdominal surgery | |||
| Laparoscopy | 22 (28.6) | 10 (31.3) | 0.9 |
| Pfannenstiel laparotomy (except cesarean section) | 10 (13.0) | 1 (3.1) | 0.17 |
| Median laparotomy | 7 (9.1) | 2 (6.3) | 1 |
* Missing data for 2 patients. ** Some patients had more than one comorbidity.
Surgical factors.
| Variables | Conventional | Low Impact | |
|---|---|---|---|
| Indication for surgery | 0.01 | ||
| Endometrial neoplasm | |||
| Endometrial cancer | 12 (15.6) | 10 (31.3) | |
| Atypical endometrial hyperplasia | 2 (2.6) | 4 (12.5) | |
| Other conditions | |||
| Cervical dysplasia | 6 (7.8) | 1 (3.1) | |
| Symptomatic Fibroma | 37 (48.1) | 10 (31.3) | |
| Adenomyosis | 13 (16.9) | 4 (12.5) | |
| Other | 7 (9.1) | 3 (9.4) | |
| Mean intraoperative pressure | <0.001 | ||
| <10 | 18 (23.4) | 28 (87.4) | |
| 10–12 | 59 (76.6) | 2 (6.3) | |
| >12 | 0 | 2 (6.3) | |
| Parietal adherences | 20 (26.0) | 6 (18.8) | 0.57 |
| Pelvic adherences | 17 (22.1) | 8 (25) | 0.93 |
| Deep pelvic endometriosis | 1 (1.3) | 3 (9.4) | 0.08 |
| Associated perioperative surgery * | |||
| Uterosacral ligament resection | 1 (1.3) | 0 | |
| Ureterolysis | 1 (1.3) | 5 (15.6) | <0.001 |
| Parametrial resection | 0 | 1 (3.1) | |
| Omentectomy, appendicectomy | 0 | 2 (6.3) | |
| Median duration of anesthesia in minutes (Q1; Q3) | 193 (167; 210.5) | 174 (147; 206) | 0.03 |
| Median duration of surgery in minutes (Q1; Q3) | 140 (118; 162) | 129 (107; 151) | 0.08 |
| Median duration of pneumoperitoneum in minutes (Q1; Q3) | 121 (98; 144) | 105 (93; 129) | 0.3 |
| Median uterus size in mm (sd) | 65 (22.5) | 63 (21.3) | 0.61 |
| Median weight of the uterus in grammes (sd) | 130 (108) | 107 (136) | 0.37 |
Unless otherwise specified, data are expressed in n (%). * Excluding adhesiolysis.
Postoperative outcomes and pain.
| Conventional Laparoscopy | Low-Impact Laparoscopy | ||
|---|---|---|---|
| Median length of stay in PACU in minutes (Q1; Q3) | 136.5 (115; 161.2) | 133 (114; 169) | 0.74 |
| Length of hospitalization (days) | <0.001 | ||
| Outpatient | 1 (1.3) | 29 (90.6) | |
| 24 h | 39 (50.6) | 2 (6.3) | |
| 48 h | 30 (39.0) | 1 (3.1) | |
| >48 h | 7 (9.1) | 0 | |
| Postoperative pain | |||
| Maximum in PACU (mean; sd) | 3.04; 2.46 | 2.06; 2.19 | 0.04 |
| Maximum pain on Day 0 (mean; sd) | 1.45; 1.84 | 1.42; 1.69 | 0.92 |
| Maximum pain on Day 1 (mean; sd) | 2.11; 1.95 | 2.64; 2.4 | 0.32 |
| Ropivacaine port infusion | 56 (72.7) | 19 (59.4) | 0.25 |
| Analgesic Consumption | |||
| Paracetamol | |||
| PACU | 22 (28.6) | 9 (28.1) | 0.96 |
| Day 0 | 14 (18.2) | 0 | < 0.001 |
| Day 1 | 17 (22.1) | 2 (6.3) | 0.055 |
| Weak or strong opioid consumption anytime | 49 (63.6) | 10 (31.3) | |
| Weak opioids (Tramadol) | |||
| PACU | 6 (7.8) | 0 | <0.001 |
| Day 0 | 8 (10.4) | 0 | <0.001 |
| Day 1 | 23 (30.0) | 4 (12.5) | 0.09 |
| Strong Opioids | |||
| PACU | 35 (45.5) | 7 (21.9) | 0.03 |
| Day 0 | 20 (26.0) | 1 (3.1) | <0.01 |
| Day 1 | 28 (36.4) | 4 (12.5) | 0.02 |
Figure 1Postoperative opioid consumption and pain evaluation by surgical approach.
Analysis of the factors associated with ever consuming opioids in the postoperative period (PACU, Day 0 or Day 1).
| Variables | Univariable Analysis | |
|---|---|---|
| OR (95% CI) | ||
| Age | 1.0 (0.99–1.01) | 0.76 |
| BMI | 1.01 (0.99–1.03) | 0.20 |
| Comorbidities | 0.94 (0.77–1.16) | 0.58 |
| Indication for hysterectomy | 1.04 (0.98–1.10) | 0.20 |
| Surgical approach | 1.38 (1.13–1.69) | 0.002 |
| Mean intraoperative pneumoperitoneum pressure | ||
| 6–8 | ref | |
| ≥9 | 1.25 (1.03–1.51) | 0.026 |
| Mean intraoperative pressure (continuous) | 1.043 (1.001–1.087) | 0.046 |
| Uterus size | 1.00 (0.99–1.00) | 0.58 |
| Adherences | 1.01 (0.83–1.23) | 0.92 |
| Duration of pneumoperitoneum | 1.00 (0.99–1.00) | 0.44 |
| Ropivacaine port infiltration | 1.11 (0.90–1.37) | 0.33 |
Figure 2Theoretical number of patients necessary to demonstrate in a trial the benefit of low impact procedure on opioids consumption.